[Comments of the German Airway League and the German Respiratory Society to the US Food and Drug Administration (FDA)'s announcement from February 18th 2010 on the use of long acting beta-2 agonists in treatment of asthma].
Kardos
P
P
Gemeinschaftspraxis & Zentrum Allergologie, Pneumologie, Schlafmedizin Klinik Maingau, Frankfurt am Main. Kardos@lungenpraxismaingau.de
Berdel
D
D
Buhl
R
R
Criée
C P
CP
Freihorst
J
J
Gillissen
A
A
Karg
O
O
Pfeifer
M
M
Magnussen
H
H
Rabe
K F
KF
Teschler
H
H
Vogelmeier
C
C
Welte
T
T
Wettengel
R
R
Worth
H
H
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000420:Albuterol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004348:Drug Labeling; D004359:Drug Therapy, Combination; D064420:Drug-Related Side Effects and Adverse Reactions; D004983:Ethanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D000068759:Formoterol Fumarate; D005858:Germany; D006801:Humans; D015201:Meta-Analysis as Topic; D017410:Practice Guidelines as Topic; D015272:Pulmonary Medicine; D000068299:Salmeterol Xinafoate; D012955:Societies, Medical; D014481:United States; D014486:United States Food and Drug Administration
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D003692:Delayed-Action Preparations; D004983:Ethanolamines; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate